Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study
نویسندگان
چکیده
منابع مشابه
Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study.
BACKGROUND Recurrent vulvovaginal candidiasis (VVC) has been linked to allergic disease, particularly allergic rhinitis. OBJECTIVE A pilot study to assess the possible use of the leukotriene receptor antagonist zafirlukast as a treatment for recurrent VVC. METHODS 20 women with six or more symptomatic attacks of VVC in the past year (at least four proved microbiologically). Clinical atopy d...
متن کاملEvidence-Based Management of Recurrent Vulvovaginal Candidiasis
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5-8% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no gold standard treatment for RVVC. Although antifungal agents such as imidazoles have been successfully used as first-line treatment for acute VVC, the effectiveness of these medications is limited for RVVC, and various...
متن کاملProbiotics for prevention of recurrent vulvovaginal candidiasis: a review.
Vulvovaginal candidiasis (VVC) is a common infection affecting the quality of life of many women. Probiotics have been investigated as possible agents for the prevention of recurrences of VVC. We reviewed the available literature. In some studies the development of VVC was associated with either a low number of lactobacilli in the vagina or with the presence of H2O2-non-producing vaginal lactob...
متن کاملBoric acid for recurrent vulvovaginal candidiasis: the clinical evidence.
BACKGROUND Recurrent vulvovaginal candidiasis (VVC) remains a challenge to manage in clinical practice. Recent epidemiologic studies indicate that non-albicans Candida spp. are more resistant to conventional antifungal treatment with azoles and are considered as causative pathogens of vulvovaginal candidiasis. METHODS We searched PubMed and Scopus for studies that reported clinical evidence o...
متن کاملMycophenolate mofetil for myasthenia gravis: an open-label pilot study.
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sexually Transmitted Infections
سال: 2004
ISSN: 1368-4973
DOI: 10.1136/sti.2002.003491